Achieve Life Sciences gets FDA complete response letter for cytisinicline NDA over manufacturing deficiencies

Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc.

ACHV

0.00
  • Achieve Life Sciences received an FDA Complete Response Letter for its cytisinicline NDA, delaying approval on manufacturing and labeling issues.
  • FDA cited cGMP deficiencies at a prior third-party plant with an Official Action Indicated classification; no clinical efficacy or safety issues were flagged.
  • Company plans to resubmit in Q4 2026 with Adare Pharma Solutions as primary manufacturer; approval now targeted for H1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220830PRIMZONEFULLFEED9750133) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.